Is PROCEPT’s Growth Targets And New CFO Director Altering The Investment Case For PROCEPT BioRobotics (PRCT)?

Simply Wall St.03-10

In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618695928?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-03-10 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618695928","market":"sg","top_or_hot":-1,"title":"Is PROCEPT’s Growth Targets And New CFO Director Altering The Investment Case For PROCEPT BioRobotics (PRCT)?","media":"Simply Wall St.","content":"<div>\n<p>In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/is-procepts-growth-targets-and-new-cfo-director-altering-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is PROCEPT’s Growth Targets And New CFO Director Altering The Investment Case For PROCEPT BioRobotics (PRCT)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs PROCEPT’s Growth Targets And New CFO Director Altering The Investment Case For PROCEPT BioRobotics (PRCT)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/is-procepts-growth-targets-and-new-cfo-director-altering-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/is-procepts-growth-targets-and-new-cfo-director-altering-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/is-procepts-growth-targets-and-new-cfo-director-altering-the","article_id":"2618695928","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/is-procepts-growth-targets-and-new-cfo-director-altering-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618695928","pubTimestamp":1773149048,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 million in revenue, gross margin of about 65%, and a net loss of US$78,500,000 to US$91,500,000.\nAlongside this guidance, the company outlined 2027 targets, including 25% to 30% annual revenue growth and 68% to 70% gross margin, and soon after expanded its board to nine members by appointing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","PRCT":"PROCEPT BioRobotics"},"translate_title":"PROCEPT的增长目标和新任首席财务官是否会改变PROCEPT BioRobotics(PRCT)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1.5},"content_text":"In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 million in revenue, gross margin of about 65%, and a net loss of US$78,500,000 to US$91,500,000. Alongside this guidance, the company outlined 2027 targets, including 25% to 30% annual revenue growth and 68% to 70% gross margin, and soon after expanded its board to nine members by appointing former Shockwave Medical CFO Daniel Puckett as an independent director and Audit Committee member, reinforcing its financial and governance oversight. We’ll now examine how PROCEPT’s 2026–2027 growth and margin guidance, alongside Daniel Puckett’s board appointment, influences its investment narrative. The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementPROCEPT BioRobotics Investment Narrative RecapTo own PROCEPT, you have to believe Aquablation can keep expanding from a relatively small installed base into a standard hospital treatment while the company manages ongoing losses. The key near term catalyst remains procedure and system growth supported by improved reimbursement, while the biggest risk is continued operating losses if growth slows. The 2026–2027 guidance and Daniel Puckett’s appointment do not fundamentally change these near term drivers, but they sharpen the focus on execution and financial discipline. The most relevant update here is PROCEPT’s 2026 guidance for US$390 million to US$410 million in revenue, roughly 65% gross margin, and a sizeable net loss. This frames how much growth the company needs from HYDROS placements and Aquablation procedure volumes to narrow losses over time. Against that backdrop, adding an experienced ex CFO to the board and Audit Committee sits directly in the context of investors watching whether higher revenue can eventually translate into a more sustainable margin profile. But while the growth story is appealing, investors should also be aware of how sustained net losses and reimbursement pressures could affect... Read the full narrative on PROCEPT BioRobotics (it's free!)PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028.Uncover how PROCEPT BioRobotics' forecasts yield a $32.50 fair value, a 29% upside to its current price.Exploring Other PerspectivesPRCT 1-Year Stock Price Chart Some of the most optimistic analysts, who were modeling revenue reaching about US$624 million and earnings of roughly US$77 million by 2028, are effectively betting that catalysts like broader Aquablation adoption will outweigh risks such as reimbursement pressure and dependence on one platform, yet this new guidance and board change could prompt those expectations to shift in very different directions, so it is worth comparing how your view stacks up against those more aggressive forecasts.Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $32.45!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.Curious About Other Options?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618695928","isCrawlerRequest":true}